| 2025-11-12 |
详情>>
股本变动：
变动后总股本2841.25万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.35美元,归母净利润-3670.4万美元,同比去年增长27.94%
|
| 2025-11-10 |
财报披露：
美东时间 2025-11-10 盘后发布财报
|
| 2025-08-15 |
详情>>
内部人交易：
SASSINE ANDY股份增加1238.00股
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-0.86美元,归母净利润-2325.6万美元,同比去年增长47.19%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-0.52美元,归母净利润-1407.6万美元,同比去年增长47.51%
|
| 2025-04-25 |
股东大会：
将于2025-06-06召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, Dr. John Markels, and Dr. Moncef Slaoui to the Board of Directors (the “Board”), to serve until our next annual meeting of stockholders.
2.To approve, on a non-binding advisory basis, the resolution approving named executive officer compensation.
3.To ratify the appointment of Deloitte & Touche LLP (“Deloitte”), as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
4.To transact other business that may properly come before the annual meeting.
|
| 2025-03-06 |
详情>>
业绩披露：
2024年年报每股收益-3美元,归母净利润-8094.1万美元,同比去年增长-172.3%
|
| 2025-03-06 |
详情>>
业绩披露：
2022年年报每股收益0.35美元,归母净利润934.90万美元,同比去年增长104.59%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.89美元,归母净利润-5093.6万美元,同比去年增长-182.7%
|
| 2024-08-05 |
详情>>
业绩披露：
2023年中报每股收益-0.07美元,归母净利润-179.6万美元,同比去年增长97.53%
|
| 2024-08-05 |
详情>>
业绩披露：
2024年中报每股收益-1.64美元,归母净利润-4403.3万美元,同比去年增长-2351.73%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-1美元,归母净利润-2681.7万美元,同比去年增长-152.84%
|
| 2024-04-29 |
股东大会：
将于2024-06-14召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, and Dr. John Markels to the Board of Directors (the “Board”), to serve until our next annual meeting of stockholders.
2.To approve an amendment to the Amended and Restated 2019 Omnibus Equity Incentive Plan (as amended, the “Plan”) to, among other things, increase the maximum number of shares of common stock available to Plan participants thereunder by 2,000,000 shares to an aggregate of 10,750,000 shares (the “Amendment”).
3.To approve, on a non-binding advisory basis, the resolution approving named executive officer compensation.
4.To ratify the appointment of Deloitte & Touche LLP (“Deloitte”), as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
5.To transact other business that may properly come before the annual meeting.
|
| 2024-03-14 |
详情>>
业绩披露：
2023年年报每股收益-1.12美元,归母净利润-2972.5万美元,同比去年增长-417.95%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.68美元,归母净利润-1801.8万美元,同比去年增长83.32%
|
| 2023-05-01 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet, Dr. Jing L. Marantz, and Dr. John Markels to the Board of Directors (the “Board”), to serve until our next annual meeting of stockholders.
2.To approve, on a non-binding advisory basis, the resolution approving named executive officer compensation.
3.To ratify the appointment of Ernst & Young LLP (“E&Y”), as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
4.To transact other business that may properly come before the annual meeting.
|
| 2022-05-02 |
股东大会：
将于2022-06-21召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet and Dr. Jing L. Marantz to the Board of Directors (the “Board”), to serve until our next annual meeting of stockholders.
2.To approve, on a non-binding advisory basis, the resolution approving named executive officer compensation.
3.To approve an amendment to the Amended and Restated 2019 Omnibus Equity Incentive Plan (as amended, the “Plan”) to, among other things, increase the maximum number of shares of common stock available to Plan participants thereunder by 3,750,000 shares to an aggregate of 9,500,000 shares and increase the annual compensation non-executive directors are eligible to receive thereunder (the “Amendment”).
4.To approve, on a non-binding advisory basis, the preferred frequency of stockholder advisory votes on executive compensation, referred to as “say-on-frequency.”
5.To ratify the appointment of Ernst & Young LLP (“E&Y”), as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-18召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet and Karah Parschauer to the Board of Directors (the “Board”), to serve until our next annual meeting of stockholders.
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To transact other business that may properly come before the annual meeting.
|
| 2020-10-13 |
股东大会：
将于2020-11-10召开股东大会
会议内容 ▼▲
- 1.To amend our Certificate of Incorporation to increase the number of shares of common stock we are authorized to issue from 30,000,000 shares to 60,000,000 shares (“Proposal 1”);
2.To approve the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt Proposal 1;
3.To transact other business that may properly come before the Special Meeting.
|
| 2020-04-29 |
股东大会：
将于2020-06-05召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet and Karah Parschauer to the Board of Directors (the “Board”), to serve until our next annual meeting of stockholders.
2.To approve our 2020 Employee Stock Purchase Plan.
3.To approve our Amended & Restated 2019 Omnibus Equity Incentive Plan (the “Amended and Restated Omnibus Plan”) which, among other things, increases the maximum number of shares of common stock reserved for delivery under the plan by 3,150,000 shares.
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
5.To transact other business that may properly come before the annual meeting.
|
| 2019-10-01 |
股东大会：
将于2019-10-25召开股东大会
会议内容 ▼▲
- 1.To elect Dr. Peter Farrell, Joseph E. Payne, Andy Sassine, James Barlow, Dr. Edward W. Holmes, Dr. Magda Marquet and Karah Parschauer to the Board of Directors to serve until our next annual meeting of stockholders.
2.To approve our 2019 Omnibus Equity Incentive Plan, inclusive of previous grants made thereunder.
3.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation.
4.To approve, by non-binding advisory vote, the frequency of future non-binding advisory votes on resolutions approving future named executive officer compensation.
5.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
6.To transact other business that may properly come before the annual meeting.
|
| 2019-01-14 |
复牌提示：
2019-01-14 09:48:47 停牌，复牌日期 2019-01-14 09:58:47
|
| 2018-07-20 |
股东大会：
将于2018-08-24召开股东大会
会议内容 ▼▲
- 1.To approve the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 and to authorize the board of directors of the Company (the “Board”) to determine its compensation.
2.To approve an amended and restated Compensation Policy for the Company’s Office Holders.
3.To approve the adoption of the Arcturus Therapeutics Ltd. 2018 Omnibus Equity Incentive Plan.
4.To approve the re-election as directors of the Board, until the next annual general meeting of the Company, of each of the following currently serving directors: Mr. Joseph Payne, Dr. Peter Farrell, Mr. Andy Sassine, Dr. Magda Marquet and Mr. James Barlow.
5.To approve the compensation terms of Dr. Peter Farrell as Chairman of the Board, and the compensation terms of Dr. Magda Marquet and Mr. James Barlow, as directors of the Company.
6.To approve the compensation terms of Mr. Andy Sassine, as director of the Company, and as interim Chief Financial Officer.
7.To approve and ratify the compensation terms of Mr. Joseph Payne, as director of the Company, President and Chief Executive Officer of the Company.
8.To approve and ratify the compensation terms of Mr. Padmanabh Chivukula, as Chief Scientific Officer and Chief Operating Officer of the Company.
9.To review and discuss the Company’s financial statements of the Company for the fiscal year ended December 31, 2017.
|
| 2018-06-01 |
股东大会：
将于2018-07-05召开股东大会
会议内容 ▼▲
- 1.Approval of the following resolution:
To remove and transfer, Messrs. Stuart Collinson, Craig Willett, Daniel Geffken and David Shapiro - as well as any other person that may be appointed to the Board pursuant to article 4.2.3 of the Articles of Association of the Company, as of the date hereof and until the EGM, including the four persons the Board may have resolved to appoint at its meeting of April 20, 2018 - from the office of directors on the Board. Such termination to be with immediate effect, so that until additional directors are appointed pursuant to resolution 3 below, only Mr. Joseph Payne will remain as director on the Board.
2.Approval of the following resolution:
To amend articles 4.2.1 and 4.2.2 of the Articles of Association of the Company, with immediate effect, so that the authority to determine the number of directors of the Company, as well as the authority to elect new directors to the Board is also provided – in any circumstances - to extraordinary general meetings of the shareholders of the Company. The proposed amendments to these articles shall come into effect upon the approval of this resolution by the EGM, and are as follows (proposed changes are underlined):“4.2.1 The number of Directors of the Company shall be determined from time to time by the Annual Meeting or an Extraordinary Meeting, provided that this shall not be fewer than 5 and not more than 11 Directors, including External Directors. The number of External Directors in the Company shall not be less than the number determined in the Companies Law.”，“4.2.2 Other than External Directors (who shall be elected and serve in office in strict accordance with the provisions of the Companies Law), the Directors in the Company shall be elected at an Annual Meeting or at an Extraordinary Meeting and shall serve in their office until the next Annual Meeting following one year from their election, or until they cease to serve in their office in accordance with the provisions of the Articles or any law, whichever is the earlier.”
3.Approval of the following resolution:
Further to the approval of resolution 2 of the agenda, or if not approved than pursuant to article 4.2.11 to the Articles of Association of the Company, to elect the following four individuals to serve as directors on the Board, effective immediately following the EGM’s approval: (a) Mr. Peter Farrell; (b) Mr. Andrew Sassine; (c) Mrs. Magda Marquet; (d) Mr. James Barlow.
4.Approval of the following resolution:
To remove Mr. Joseph Payne from his role as a Director on Arcturus’ Board, with immediate effect.
|
| 2018-03-13 |
股东大会：
将于2018-05-07召开股东大会
会议内容 ▼▲
- 1.Approval of the removal of Messrs. Stuart Collinson, Craig Willett, Daniel Geffken and David Shapiro from their roles as Directors on Arcturus’ Board, with immediate effect.
2.To amend articles 4.2.1 and 4.2.2 of the Articles of Association of Arcturus, with immediate effect, so that the authority to determine the number of directors of the Company, as well as the authority to elect new directors to the Board, is also provided to extraordinary general meetings of the shareholders of the Company, as follows (new language underlined):
3.If Proposal 2 is approved by the shareholders at the EGM, to elect the following four individuals to serve as directors on the Board, effective immediately following the EGM: Peter Farrell, Andrew Sassine, Magda Marquet and James Barlow. If Proposal 2 is not approved by the shareholders at the EGM, Proposal 3 will not be voted on by the shareholders at the EGM.
4.Approval of the removal of Mr. Joseph Payne from his role as a Director on Arcturus’ Board, with immediate effect.
5.Ratification of the appointment of Ernst & Young LLP as Arcturus’ independent auditors for the audit of Arcturus’ financial statements for the year ended December 31, 2017 and for the additional period until Arcturus’ annual meeting of shareholders in 2018.
6.To approve the adjournment or postponement of the EGM until a later date, time and venue as determined by the chairperson of the EGM (subject to any required notification under Israeli
|
| 2018-02-05 |
股东大会：
将于2018-02-26召开股东大会
|
| 2017-11-16 |
详情>>
拆分方案：
每7.0000合并分成1.0000股
|
| 2017-09-14 |
股东大会：
将于2017-10-19召开股东大会
会议内容 ▼▲
- 1.To present the financial statements of Alcobra for the fiscal year ended December 31, 2016.
2.To re-appoint Kost, Forer, Gabbay & Kasierer (a member of Ernst & Young Global) as Alcobra’s independent registered public accounting firm until the next Annual Meeting and to authorize Alcobra’s Board of Directors to determine its compensation for the fiscal year ending December 31, 2017.
3.Re-election of the following Alcobra’s currently serving directors: Mr. Howard B. Rosen, Dr. Yaron Daniely, Mr. Daniel E. Geffken, Dr. Aharon Schwartz, Mr. Arieh Ben Yosef, Mr. Ofer Segev and Ms. Orli Tori.
4.Election of Mr. Yuval Yanai as a Director and approval of his terms of compensation.
5.Election of Mr. Amir Efrati as a Director.
6.To approve an amendment to Alcobra’s Option Plan.
7.To approve the terms of compensation of Mr. David Baker, as interim Chief Executive Officer of the Company.
8.To approve the grant of options to Dr. Yaron Daniely for his services as Alcobra’s Chairperson of Board of Directors and past services as former Chief Executive Officer.
9.To approve grant of options to certain directors of Alcobra.
|
| 2016-06-08 |
股东大会：
将于2016-07-19召开股东大会
会议内容 ▼▲
- 1. To present the financial statements of the Company for the fiscal year ended December 31, 2015.
2. To re-appoint Kost, Forer, Gabbay & Kasierer (a member of Ernst & Young Global) as the Company's independent registered public accounting firm until the next Annual Meeting and to authorize the Company's Board of Directors to determine its compensation for the fiscal year ending December 31, 2016.
3. Re-election of the following Company’s currently serving directors: Mr. Howard B. Rosen, Dr. Yaron Daniely, Dr. Joao Siffert, Mr. Daniel E. Geffken, Dr. Aharon Schwartz, and Mr. Arieh Ben Yosef.
4. Election of Mr. Ofer Segev as a Director and approval of his terms of compensation.
5. Election of Ms. Orli Tori as a Director and approval of her terms of compensation.
6. To approve an amendment to the Compensation Policy for Company Office Holders.
7. To approve an amendment to the Company's Option Plan.
8. To approve an amendment of the Chief Executive Officer Compensation.
9. To approve grant of options to certain directors of the Company.
|
| 2015-06-03 |
股东大会：
将于2015-07-13召开股东大会
会议内容 ▼▲
- 1.To present the financial statements of the Company for the fiscal year ended December 31, 2014.
2.Re-appointment of Kost, Forer, Gabbay & Kasierer (a member of Ernst & Young Global) as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2015 and to authorize the Company's Board of Directors to determine its compensation.
3.Re-election of the following Company’s current serving directors: Mr. Howard B. Rosen, Dr. Yaron Daniely, Dr. Aharon Schwartz, Mr. Daniel E. Geffken and Mr. Arieh Ben Yosef.
4.Election of Dr. Joao Siffert as a Director and approval of his remuneration terms.
5.Approval of an amendment to the Compensation Policy for Company Office Holders.
6.Approval of the Company's Option Plan.
7.Approval of a grant of options to Dr. Yaron Daniely, the Company’s CEO and President and a director.
8.Approval of a grant of options to Mr. Arieh Ben Yosef, a director of the Company.
|